Solexan (arginine undecylenate)
/ Wintermute Biomedical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 10, 2025
ZOSTER EASE: WNTR-VZV-001: A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Solexan™ when Administered Topically to Acute Varicella Zoster Virus (Shingles) Lesions.
(ANZCTR)
- P1 | N=30 | Completed | Sponsor: Wintermute Biomedical | Recruiting ➔ Completed
Trial completion • Herpes Zoster • Infectious Disease • Varicella Zoster
1 to 1
Of
1
Go to page
1